$-0.04
(Market cap
$8 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
10.8
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-3.7 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-3.1
-
Debt to Equity
--
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
4,825,723
7 Years Aggregate
CFO
$-25.11 Mln
EBITDA
$-41.55 Mln
Net Profit
$-41.75 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Alzamend Neuro Inc (ALZN)
| -8.8 | 23.9 | 44.3 | -29.7 | -65.8 | -67.7 | -- |
|
BSE Sensex*
| -10.1 | -3.6 | 2.5 | -5.7 | 4.9 | 5.5 | 10.1 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Alzamend Neuro Inc (ALZN)
| 56.9 | -86.7 | -89.5 | -70.3 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Alzamend Neuro Inc (ALZN)
|
1.7 | 8.0 | 0.0 | -8.8 | -- | -373.2 | -- | 10.8 |
| 3.1 | 104.5 | 0.0 | -10.1 | -- | -67.4 | -- | 7.2 | |
| 72.4 | 11,358.4 | 1,215.0 | 181.9 | 20.3 | 9 | 62.4 | 5.4 | |
| 2.0 | 16.9 | 0.0 | -22.1 | -- | -0 | -- | 1.9 | |
| 5.2 | 72.5 | 59.4 | -1.2 | -1.6 | -30.5 | -- | 17.7 |
Shareholding Pattern
View DetailsAbout Alzamend Neuro Inc (ALZN)
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination... of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia. Read more
-
CEO & Director
Mr. Stephan Jackman
-
Founder & Vice Chairman
Mr. Milton Charles Ault III
-
Headquarters
Atlanta, GA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Alzamend Neuro Inc (ALZN)
What is the current share price of Alzamend Neuro Inc (ALZN) Today?
The share price of Alzamend Neuro Inc (ALZN) is $1.66 (NASDAQ) as of 04-Sep-2026 16:20 EDT. Alzamend Neuro Inc (ALZN) has given a return of -65.77% in the last 3 years.
What is the current PB & PE ratio of Alzamend Neuro Inc (ALZN)?
Since, TTM earnings of Alzamend Neuro Inc (ALZN) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2026 |
-- |
-- |
2025 |
-- |
-- |
2024 |
-- |
-- |
2023 |
-- |
-- |
2022 |
-- |
-- |
What is the 52 Week High and Low of Alzamend Neuro Inc (ALZN)?
The 52-week high and low of Alzamend Neuro Inc (ALZN) are Rs 2.68 and Rs 0.85 as of 08-Sep-2026.
What is the market cap of Alzamend Neuro Inc (ALZN)?
Alzamend Neuro Inc (ALZN) has a market capitalisation of $ 8 Mln as on 04-Sep-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Alzamend Neuro Inc (ALZN)?
Before investing in Alzamend Neuro Inc (ALZN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.